Table 1.

Summary of patient characteristics at enrollment

Patient characteristics
No. patients18
Age (y), median (range)74.4 (51-83)
Race, n (%)
    Caucasian15 (83)
    African American3 (17)
ECOG performance status, n (%)
    016 (89)
    12 (11)
PSA (ng/mL), n = 18119 (4-2,047)*
PTH (pg/mL), n = 1769 (32-396)
Patients with bone metastases, n (%)14 (78)
Patients with elevated PTH, n (%)7 (41)
Alkaline phosphatase (units/L), n = 17118 (72-4,302)
Calcium (albumin corrected, mg/d), n = 189.4 (8.1-10.2)
Albumin (g/dL), n = 184.1 (3.5-4.4)
Phosphorus (mg/dL), n = 183.5 (2.6-3.7)
Creatinine (mg/dL), n = 171.3 (1-1.7)
25-Hydroxyvitamin D (ng/mL), n = 1619.5 (8-34)
Ca × P (mg2/dL2, corrected), n = 1831.6 (25.6-36.7)
  • NOTE: Data are given as medians and ranges.

    Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • * One patient, whose PSA at entry was <10, was entered into the trial in error.